Anti-DR5 [TRA-8]

Absolute Antibody

Anti-DR5 [TRA-8]

9

The antibody is specific to human DR5 and does not bind other TRAIL receptors, other members of the TNF-receptor superfamily, or the murine homolog of DR5.

The antibody has been characterised using Western blot and ELISA. It induces apoptosis in primary hepatocellular carcinoma cells and established liver cancer cell lines, but not normal human hepatocytes (Ichikawa et al., 2001). The antibody has been reported to function in flow cytometry to detect cell-surface expression of DR5 on Cos-7 cells transfected with full-length human DR5. This antibody has been demonstrated to have therapeutic benefits in the treatment of cancer in vivo and ex vivo (Buchsbaum et al., 2003; PMID: 14506165) (Straughn Jr et al., 2006; PMID: 16271751) (Estes et al., 2007; PMID: 17303227).

Flow Cytometry, Western Blot, ELISA

Research Use Only

Monoclonal

TRA-8

TNFRSF10B

TNF receptor superfamily member 10b

apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; DR5; Fas-like protein; KILLER; KILLER/DR5; p53-regulated DNA damage-inducible cell death receptor(killer); TNF-related apoptosis-inducing ligand receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9

Mouse

IgG1

Tumor necrosis factor receptor superfamily member 10B

Human

-20°C,2°C to 8°C

12352203